Overview

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that omalizumab may reduce the rate of systemic reactions to immunotherapy in patients with persistent allergic asthma.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Collaborators:

Genentech, Inc.
Tanox

Treatments:

Immunologic Factors
Omalizumab